Friday, August 24th, 2018, Rockville, MD - Insilico Medicine, a Rockville-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its CTO, Alex Zhebrak at the 5th Global Precision Medicine & Biomarkers Leaders Summit, September 13-14, 2018, Munich, Germany.
On September 13-14th, the 5th Global Precision Medicine & Biomarkers Leaders Summit: Europe will detail the latest research on the strategies and technology required to facilitate Precision Medicine. Industry and academic leaders will be examining ground-breaking biomarker, companion diagnostic, immuno-oncology, genomic, big data and AI research to facilitate the development of impactful personalized treatments. With over 30 presentations, expert led panel discussions, in depth roundtable sessions and 7+ hours of dedicated time for networking, this is an event not to be missed. View agenda here.
Alex Zhebrak will give a talk titled "End-to-end machine learning engine for drug discovery", will cover Insilico's approach finding the most promising targets and generating novel molecular structures for drug discovery.
"Machine learning techniques have been widely adopted in multiple research fields over the recent years including bioinformatics, chemistry, and drug discovery. Novel computational methods and generative models can discover promising targets and drug compounds within hours, while conventional drug design pipelines require months of work. Insilico Medicine focuses on applications of machine learning to biomarker development and early-stage drug discovery. The talk will explore our end-to-end learning pipeline, which utilizes multiple data types to identify the most promising targets and generates novel molecular structures with the desired set of parameters", said Alex Zhebrak.
"Machine learning techniques found its applications in several areas, including realistic image synthesis, text-to-image synthesis or even animating movie, etc Vast amounts of data collected within pharmaceutical industry can be utilised to build similar models. Nowadays, the target itself is not a competitive advantage, in most cases the value is in a molecule. At Insilico Medicine, we build GANs that work on multiple representations of the chemical structures to expand and navigate through the chemical space. Automated discovery of novel chemotypes with certain properties against specific targets offered by GANs shows a great promise to significantly facilitate early drug design stages", said Alex Aliper, President of EMEA at Insilico Medicine, Inc.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. The paper published in Molecular Pharmaceutics in 2016 demonstrated the first proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.
For further information, images or interviews, please contact:
Contact: Qingsong Zhu, PhD
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered at in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. The company and its scientists is dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/